Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 165 of 255 results for radiotherapy

  1. Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (HTG333)

    Evidence-based recommendations on electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma. This involves injecting a chemotherapy drug into the tumour and using electrical pulses to increase its effect.

    HealthTech guidance
    Published
    26 February 2014
    View recommendations

    Sections for HTG333

  2. Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)

    Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    13 May 2020
    View recommendations

    Sections for TA628

  3. Focal therapy using cryoablation for localised prostate cancer (HTG284)

    Evidence-based recommendations on focal therapy using cryoablation for localised stage prostate cancer. This involves using freezing (cryotherapy) needles to find and destroy only the cancerous part of the prostate.

    HealthTech guidance
    Published
    26 April 2012
    View recommendations

    Sections for HTG284

  4. Radiation-induced lymphopenia and risk of new COVID-19 and severity of COVID-19: Does radiation-induced lymphopenia predispose patients to an increased risk of new COVID-19 and does it contribute to patients developing more severe COVID-19?

    Comes from guidance COVID-19 rapid guideline: delivery of radiotherapy Number NG162 Date issued March 2020 Other details

    Research recommendation
    Published
    21 October 2021

  5. Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)

    Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer.

    Technology appraisal guidance
    Last updated
    10 August 2017
    View recommendations

    Sections for TA190

  6. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)

    Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults.

    Technology appraisal guidance
    Published
    17 October 2018
    View recommendations

    Sections for TA544

  7. Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]

    In development Reference number: GID-TA11093 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Radical treatment of squamous cell carcinoma of the oesophagus:- Does the addition of surgery to chemoradiotherapy improve disease-free and overall survival inpeople with squamous cell carcinoma of the oesophagus?

    Standard radical treatment for SCC of the oesophagus is usually chemo-radiotherapy, which is associated with a median survival of...

    Research recommendation
    Published
    13 November 2018

  9. L-Dex U400 for lymphoedema after breast cancer treatment (MIB111)

    NICE has developed a medtech innovation briefing (MIB) on L-Dex U400 for lymphoedema after breast cancer treatment .

    Medtech innovation briefing
    Published
    4 July 2017

  10. Oesophago-gastric cancer (QS176)

    This quality standard covers assessing and managing oesophago-gastric cancer in adults. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    13 December 2018
    View quality statements

    Sections for QS176

  11. Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)

    Evidence-based recommendations on treosulfan (Trecondi) with fludarabine for conditioning treatment before allogeneic haematopoietic stem cell transplant for malignant diseases in people for whom a reduced intensity regimen would be suitable.

    Technology appraisal guidance
    Published
    5 August 2020
    View recommendations

    Sections for TA640

  12. Rapid genetic testing:- Research is recommended to determine the benefits and harms of creating rapid access to genetic testing for people with newly diagnosed breast cancer. This research should address the optimum model for service delivery and organisation, the clinical and cost effectiveness of such a change, uptake outcomes and patients' experience. [new 2013]

    example, initial treatment by wide local excision often necessitates radiotherapy, which makes an acceptable cosmetic operation more...

    Research recommendation
    Published
    9 June 2015

  13. Fertility problems: assessment and treatment (CG156)

    This guideline covers diagnosing and treating fertility problems. It aims to reduce variation in practice and improve the way fertility problems are investigated and managed.

    Clinical guideline
    Last updated
    6 September 2017
    View recommendations

    Sections for CG156

  14. Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies (TA786)

    Evidence-based recommendations on tucatinib (TUKYSA) for HER2-positive locally advanced or metastatic breast cancer in adults after 2 or more anti-HER2 treatment therapies.

    Technology appraisal guidance
    Published
    27 April 2022
    View recommendations

    Sections for TA786

  15. Next-generation sequencing panel for solid tumour cancers in children (MIB133)

    NICE has developed a medtech innovation briefing (MIB) on the next-generation sequencing panel for solid tumour cancers in children .

    Medtech innovation briefing
    Published
    8 January 2018